Evidence map›Paper›PMID 41965576›Full record

ArticleBMC women's health2026

Serum 25-hydroxyvitamin D levels among women newly diagnosed with breast cancer at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.

Mehari Meles, Gadissa Gutema, Melaku Tsegaye, Chala Bashea, Feyissa Challa, Demiraw Bikila, Gebremedhin Gebremicael, Tigst Getahun, Wossene Habtu, Mekdes Alem and 3 more

Abstract read
In one paragraph

Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mehari MelesEthiopian Public Health Institute, Addis Ababa, Ethiopia. meharimeles89@gmail.com.
Gadissa GutemaEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Melaku TsegayeCollege of Health Sciences, Wolaita Sodo University, Wolaita Sodo, Ethiopia.
Chala BasheaEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Feyissa ChallaEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Demiraw BikilaEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Gebremedhin GebremicaelEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Tigst GetahunEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Wossene HabtuEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Mekdes AlemCollege of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Abebe EdaoCollege of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Anna CarobeneLaboratory Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Habteyes Hailu TolaCollege of Health Sciences, Salale University, Fitche, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer (BC) is among the most frequently diagnosed cancers in women, accounting for approximately one in ten new cancer cases annually. The relationship between vitamin D status and BC risk remains unclear; while some observational studies suggest an association, others show no link, and causality is unproven. However, data from sub-Saharan Africa, and specifically Ethiopia, are scarce. This study aimed to assess serum 25-hydroxyvitamin D [25(OH)D] levels in Ethiopian women newly diagnosed with BC compared to healthy controls.

methodsA comparative cross-sectional study was conducted from January to March 2024 at Tikur Anbessa Specialized Hospital, Addis Ababa. Sixty-nine women with newly diagnosed BC and sixty-nine healthy controls were enrolled. Serum 25(OH)D concentrations were measured via electrochemiluminescence immunoassay. Data analysis was performed with SPSS v20. Median differences were evaluated using the Mann–Whitney U test with Hodges–Lehmann estimates and 95% confidence intervals (CI). Logistic regression identified factors associated with BC, and sensitivity analyses were conducted using alternative clinical cut-offs for severe vitamin D deficiency (SVDD).

resultsVitamin D deficiency was prevalent in both groups; however, SVDD (< 10 ng/mL) was significantly more prevalent among BC patients than among controls (26.1% vs. 7.2%, p = 0.006). A significant median difference in 25(OH) D levels was observed between cases and controls (median difference: 2.1 ng/mL; 95% CI: 0.07–4.4; p = 0.043). Serum 25(OH)D levels were also significantly lower in stage IV BC compared with controls and stage I. SVDD was independently associated with BC (adjusted odds ratio = 7.1; 95% CI: 1.7–30.1), and this association remained robust when alternative clinical cut-offs were applied. Reduced sunlight exposure and overweight/obesity were also independently associated with BC.

conclusionSVDD and higher Body Mass Index were significantly associated with BC status. Lower 25(OH)D levels are most pronounced in metastatic (Stage IV) disease. While reduced sunlight exposure was also associated with BC, the direction of these relationships cannot be determined with certainty. These findings highlight an association that warrants further investigation. Further prospective studies with pre-diagnostic 25(OH)D measurements are needed to clarify causality and to determine whether strategies to address VDD may contribute to BC risk reduction.

Indexed as

Breast NeoplasmsVitamin DVitamin D DeficiencyAdultCase-Control StudiesCross-Sectional StudiesEthiopiaFemaleHumansMiddle AgedPrevalenceRisk Factors25-hydroxyvitamin DVitamin D25-Hydroxyvitamin DBreast CancerCancerVitamin D deficiency

Identifiers

PMID41965576
PMCPMC13217863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.